You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
AdGeniX started distributing Yourgene's Iona test in France in 2015 and has rapidly grown sales for the test, a trend that is expected to continue.
Earlier this month, the company started accepting clinical samples at its CLIA/CAP laboratory in Pittsburgh and an affiliate laboratory in Malaysia.
Researchers at Baylor College of Medicine and Columbia University found that almost all blood samples from pregnant women tested contained several trophoblasts.
Yourgene said it continues to consider additional acquisition opportunities to enhance its earnings and to acquire complementary technologies.
A preliminary analysis lends some support to covering NIPS for pregnancies beyond high-risk, and some payors have expanded coverage.
The company processed more than 200,000 tests during the quarter, an increase of 20 percent compared to the 167,000 tests it processed in Q3 of last year.
The company said three clinical centers have validated the test in a prospective clinical trial involving more than 10,000 participants.
Next week at the American Society of Human Genetics annual meeting, LabCorp researchers plan to present results from almost 1,000 triplet pregnancies.
The company published a quality assurance study for the Panorama test last month and is wrapping up the SMART study, which has enrolled 20,000 women.
The first application of the technology will be for noninvasive prenatal screening followed by cancer liquid biopsy testing.